Meningomyeloproliferative syndrome, or meningosarcoidosis (MMPS), or sarcoid meningitis (SM) is a rare disease manifested by simultaneous or sequential damage to the joints, nervous system, skin and internal organs. First described by Louis Barker and Clara Hayes in 1960 as a rare lesion of the central nervous system (CNS).
Symptoms are accompanied by fever, elevated ESR, peripheral lymphadenopathy, weakness, hearing and vision impairment. Most patients experience characteristic changes in the bone marrow. A blood test reveals an increase in the number of red and white blood cells, hyperthrombocytosis, and extramedullary foci of hematopoiesis.
A neurological examination reveals partial impairments of cognitive functions, motor and sensory development. An important symptom of the disease is the high frequency of local lesions of the central nervous system with typical histological changes and the detection of a monoclonal component of MPO. MPS is a syndrome that includes lesions of other organs and systems that are caused by the circulation of tumor lymphocytes. To verify the diagnosis, the complex of studies includes:
- general blood analysis; - biochemical blood test against the background of hyperglobulinemia; - study of inflammatory markers: CRP, RF, AST, ALAT